Annovis Bio
Annovis Bio is a pioneering company focused on developing transformative therapies for neurodegenerative diseases such as Alzheimer's and Parkinson's. Their mission is to restore nerve cell function and improve cognitive and motor abilities in patients by targeting multiple neurotoxic proteins with innovative treatments like buntanetap. The company is committed to scientific advancement, extensive patent protection, and improving patient outcomes through groundbreaking research and clinical trials.
Industries
Nr. of Employees
small (1-50)
Annovis Bio
Patents
(3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8ahexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods of treating or preventing neurodegeneration
US-12144798-B2
View DetailsPrevention or treatment of disease states due to metal dis-homeostasis via administration of Posiphen to healthy or sick humans
US-11596621-B2
View Details(3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods of treating or preventing neurodegeneration
US-11400075-B2
View Details(3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods of treating or preventing neurodegeneration
US-11382893-B2
View Details(3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods of treating or preventing neurodegeneration
US-11376238-B2
View Details
(3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8ahexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods of treating or preventing neurodegeneration
US-12144798-B2
View DetailsPrevention or treatment of disease states due to metal dis-homeostasis via administration of Posiphen to healthy or sick humans
US-11596621-B2
View Details(3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods of treating or preventing neurodegeneration
US-11400075-B2
View Details(3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods of treating or preventing neurodegeneration
US-11382893-B2
View Details(3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate and methods of treating or preventing neurodegeneration
US-11376238-B2
View DetailsProducts
Orally administered small-molecule translational inhibitor (clinical-stage candidate)
An oral small-molecule translational inhibitor intended to reduce pathology-associated protein translation in injured neurons; evaluated in early and late-stage clinical trials with associated biomarker and clinical assessments.
Buntanetap
An orally available small molecule translational inhibitor of neurotoxic aggregating proteins designed to simultaneously target multiple proteins such as APP, tau, alpha-synuclein, and TDP-43 to treat neurodegenerative diseases.
ANVS 301
An investigational drug candidate for the treatment of advanced Alzheimer's disease.
ANVS405
Investigational compound studied for neuroprotection, restoration of dopamine levels, and reduction of inflammation in neurotrauma and CNS models.
ANVS 405
An investigational drug candidate for the treatment of traumatic brain injury and stroke.
Orally administered small-molecule translational inhibitor (clinical-stage candidate)
An oral small-molecule translational inhibitor intended to reduce pathology-associated protein translation in injured neurons; evaluated in early and late-stage clinical trials with associated biomarker and clinical assessments.
Buntanetap
An orally available small molecule translational inhibitor of neurotoxic aggregating proteins designed to simultaneously target multiple proteins such as APP, tau, alpha-synuclein, and TDP-43 to treat neurodegenerative diseases.
ANVS 301
An investigational drug candidate for the treatment of advanced Alzheimer's disease.
ANVS405
Investigational compound studied for neuroprotection, restoration of dopamine levels, and reduction of inflammation in neurotrauma and CNS models.
ANVS 405
An investigational drug candidate for the treatment of traumatic brain injury and stroke.
Services
Operational delivery of Phase 1–3 clinical studies including protocol implementation, site network activation, patient enrollment and safety monitoring.
Development and application of assays to measure disease-related plasma biomarkers and pharmacodynamic readouts to support trials.
In vivo testing in transgenic and injury models to assess neuropathology, behavior, and target engagement prior to clinical testing.
Management and coordination of GMP manufacturing partners to produce clinical trial material for late-stage studies.
Operational delivery of Phase 1–3 clinical studies including protocol implementation, site network activation, patient enrollment and safety monitoring.
Development and application of assays to measure disease-related plasma biomarkers and pharmacodynamic readouts to support trials.
In vivo testing in transgenic and injury models to assess neuropathology, behavior, and target engagement prior to clinical testing.
Management and coordination of GMP manufacturing partners to produce clinical trial material for late-stage studies.
Expertise Areas
- Neurodegenerative disease drug development
- Clinical trial management and site operations
- Biostatistics and clinical data analysis
- Biomarker discovery and bioanalytical assay development
Key Technologies
- mRNA translation modulation via 5'UTR regulatory protein stabilization
- Oral small-molecule therapeutics
- Plasma and bioanalytical biomarker assays
- PK/PD modeling and cross-species pharmacokinetics
News & Updates
Annovis will participate in AAIC 2025 with four poster presentations, showcasing their latest research and developments.
Annovis has received acceptance from the NYSE for their plan to regain compliance and maintain their listing.
Annovis will host a webinar and live Q&A session to discuss their latest updates and research progress.
Annovis announced that the first two patients have been entered into the pivotal Phase 3 study evaluating buntanetap in early AD.
Annovis published a new article on the pharmacokinetic profiles of Posiphen (or buntanetap) across different species in the journal Biomolecules.
A study comparing the pharmacokinetics of Posiphen across various species, highlighting absorption and metabolism similarities.
Annovis will participate in AAIC 2025 with four poster presentations, showcasing their latest research and developments.
Annovis has received acceptance from the NYSE for their plan to regain compliance and maintain their listing.
Annovis will host a webinar and live Q&A session to discuss their latest updates and research progress.
Annovis announced that the first two patients have been entered into the pivotal Phase 3 study evaluating buntanetap in early AD.
Annovis published a new article on the pharmacokinetic profiles of Posiphen (or buntanetap) across different species in the journal Biomolecules.
A study comparing the pharmacokinetics of Posiphen across various species, highlighting absorption and metabolism similarities.